Personalizing KRAS-Mutant Allele-Specific Therapies

Falcomata, C., Schneider, G., and Saur, D. (2020). Cancer Discov 10, 23-25. doi: 10.1158/2159-8290.CD-19-1261.


KRAS(G12R) mutations occur almost exclusively in pancreatic ductal adenocarcinoma. The results of a study that reveals specific differences in KRAS downstream signaling and metabolic rewiring of pancreatic cancer cells harboring KRAS(G12R) mutations promise to improve our possibilities to better stratify patients for individualized therapies.